Vidac Pharma Holding Plc

Based in the UK, Vidac Pharma Holding Plc specializes in innovative biopharmaceutical products focused on oncology and dermatology, including the development of advanced therapies for cancer treatment. Vidac Pharma Holding Plc, founded in 2011, operates from London, UK. The company specializes in pioneering biopharmaceutical innovations, particularly in oncology and dermatology. It has successfully completed 2 deals to date, with the most recent deal occurring on November 7, 2024.

In this round, Vidac Pharma raised EUR 600,000 in venture funding, which will be utilized to continue its clinical trials. Vidac Pharma specializes in pioneering biopharmaceutical products focusing on oncology and dermatology. The company’s primary product offering is VDA-1102, an innovative drug candidate aimed at treating advanced Actinic Keratosis (AK) and Cutaneous T-cell Lymphoma (CTCL). Utilizing Vidac’s proprietary Novel Chemical Entities (VDA-NCEs), these treatments work by reversing the Warburg effect, thereby inhibiting tumor hyper-growth and reactivating the immune response to combat cancer proliferation.

Vidac Pharma targets healthcare providers and institutions as its primary customer base, ensuring that their advanced therapies reach patients suffering from these oncologic and dermatologic conditions. The geographical markets for these products primarily include North America and Europe, where there is a significant demand for novel cancer therapies. Vidac Pharma's revenue model is centered around partnerships with healthcare providers and institutions to distribute its products, particularly VDA-1102. The company engages in B2B transactions, where healthcare providers purchase the drug candidates for use in clinical settings, focusing on hospitals and specialized treatment centers.

This structure may include agreements for exclusive distribution rights in certain territories, enabling tailored pricing strategies based on market demand and competitor positioning. Revenue is generated through direct sales transactions, potentially structured around contractual agreements that specify delivery schedules and quantities. The emphasis on first-in-class medicines positions Vidac to capture a share of the growing market for advanced oncology treatments, leveraging its innovative approach to cancer care. Vidac Pharma plans to leverage the recently raised EUR 600,000 in venture funding to advance its ongoing series of clinical trials.

The company is focused on launching new products, including VDA-1102, which is poised to significantly impact the oncology market. Additionally, Vidac aims to expand its reach into new geographic regions, particularly targeting North America and Europe, as it seeks to meet the increasing demand for advanced cancer therapies. This strategic focus is expected to enhance its market presence and drive future growth.